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Abstract: Multiple myeloma is a malignant expansion of plasma cells and aggressively affects bone
health. We show that P2X7 receptor altered myeloma growth, which affects primary bone cells
in vitro. Expression on six human myeloma cell lines confirmed the heterogeneity associated with
P2X7 receptor. Pharmacology with 2′(3′)-O-(4-benzoylbenzoyl) adenosine 5′-triphosphate (BzATP) as
agonist showed dose-dependent membranal pores on RPMI-8226 (p = 0.0027) and blockade with P2X7
receptor antagonists. Ca2+ influx with increasing doses of BzATP (p = 0.0040) was also inhibited with
antagonists. Chronic P2X7 receptor activation reduced RPMI-8226 viability (p = 0.0208). No apoptosis
or RPMI-8226 death was observed by annexin V/propidium iodide (PI) labeling and caspase-3
cleavage, respectively. However, bromodeoxyuridine (BrdU) labelling showed an accumulation of
RPMI-8226 in the S phase of cell cycle progression (61.5%, p = 0.0114) with significant decline in
G0/G1 (5.2%, p = 0.0086) and G2/M (23.5%, p = 0.0015) phases. As myeloma pathology depends on a
positive and proximal interaction with bone, we show that P2X7 receptor on RPMI-8226 inhibited the
myeloma-induced suppression on mineralization (p = 0.0286) and reversed the excessive osteoclastic
resorption. Our results demonstrate a view of how myeloma cell growth is halted by P2X7 receptor
and the consequences on myeloma–osteoblast and myeloma–osteoclast interaction in vitro.
Keywords: P2X7 receptor; myeloma; osteoblasts; osteoclasts
1. Introduction
Multiple myeloma (MM) is a malignant growth of plasma cells and a unique neoplasia of
hematologic origin. The latter is due to the bone-related complications in approximately 90% of MM
patients owing to excessive bone destruction and insufficient bone formation [1]. Factors released
during the bone remodeling favor myeloma growth and, in turn, myeloma cells contribute to cytokines
that disrupt homeostatic bone turnover. Bisphosphonates are the mainstay treatment to preserve bone
integrity, but morbidity and mortality remain significant [2]. Strategies counteracting the dependence of
MM growth on the bone microenvironment have guided key discoveries including immunomodulators,
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surface antibodies, and immune checkpoint agents [3]. Whilst advances have extended survival in
many patients, more avenues are needed to achieve a complete remission.
From an evolutionary standpoint, purines (adenosine-5′-triphosphate (ATP) and derivatives,
ADP and adenosine) and pyrimidines (uridine-5′-triphosphate and uridine diphosphate) serve multiple
purposes in living organisms. Other than a classical role in energy metabolism, they drive cellular
proliferation, differentiation, and survival via specific cell-membrane receptors called purinergic P2
receptors (P2XR and P2YR) [4]. Basal purine and pyrimidine level and a steady-state P2 receptor
activation sustain homeostasis in virtually all tissues [5]. In contrast, transient increases of ATP
above steady-state levels are a signal of cellular stress. Subsequent defense responses involve
purinergic signaling and layers of inflammatory pathways, such as those described in tumoral
immunity [6,7]. Models of solid tumors conclusively show elevated ATP (extracellular ATP, eATP)
in the tumor microenvironment (TME) thanks to innovative breakthroughs in methods of eATP
detection [8–10]. These noninvasive measurements from pericellular spaces show eATP in levels of
magnitude 103–104 times higher in the TME compared to healthy tissues (10−9–10−6 M) [10,11]. Thus,
the importance of eATP has gathered most of the attention in the field of tumor biology. P2XR are more
faithful to activation by ATP compared to P2YR and while P2XR subtypes 1–6 are engaged by lower
levels of eATP (<10−6 M), P2XR subtype 7 (P2X7 receptor) requires higher eATP (>10−6 M) [12]. Features
of P2X7 receptor involvement in cancer invasion/metastases in a variety of tumors is extensively
reviewed [13–15].
In addition to the intrinsic properties of cancer cells and the biologics within TME, expression of
P2X7 receptor on cancer cells or the host is also significant for malignant expansion [16,17]. The majority
of evidence favors P2X7 receptor antagonism as a promising anti-cancer therapy [18]; however, P2X7
receptor-dependent apoptosis of epithelial cells can be a chemotherapeutic approach in cervical
cancer [19]. Indirect effects where ATP triggers P2X7 receptor-induced immunogenicity and resolution
of ATP signal such as with hydrolyzing enzymes (CD39 and CD73) generate a metabolic halo with
contrasting immunosuppressive effects [6], blending purinergic signaling with tumor-immunology.
Regulation of the immune system is intimately connected to the hematopoietic tissue—diseases
affecting one will also affect the other. Understanding the participation of ATP and P2X7 receptor
in hematological malignancies may therefore also lay the groundwork to combat tumor-induced
immune suppression.
Direct effects of P2X7 receptor in myeloma biology are presented by in vitro studies [20,21].
However, this ATP/P2X7 receptor dependence is also reported in non-malignant peripheral blood and
splenic B cells of human and murine origin, respectively [22], thus being non-specific to myeloma.
The most common symptom of MM is bone pain and a direct function of P2X7 receptor in cancer-induced
bone pain is unclear. P2X7 receptor antagonism in pre-clinical models are described [23,24] but despite
accumulating evidence, the potential of the P2X7 receptor as an analgesic target remains unclear [25].
Discrepancies in findings are attributed to different treatment modalities, administration sites, potency,
and kinetics of each drug candidate, and even then, any clinical relevance is limited by variations in
the P2X7 receptor structure between rodents and humans.
In the present study, we address that P2X7 receptor alters myeloma growth and the
downstream events following P2X7 receptor activation. Six human multiple myeloma cell lines
(HMCLs)—RPMI-8226, U266, NCI-H929, OPM2, JJN3, and KMS12—were characterized. Expression of
two transcript variants that alter P2X7 receptor function were determined by RT-PCR, and protein
was visualized with two antibodies for specific but different epitopes on the P2X7 receptor.
Functional features such as pore formation and ion channel, using pharmacological agents such
as 2′(3′)-O-(4-benzoylbenzoyl) adenosine 5′-triphosphate (BzATP, more potent agonist than eATP) and
antagonists with varying potency at the human P2X7 receptor were tested. We chose RPMI-8226 to
identify events altered with P2X7 receptor activation. Lastly, we show that P2X7 receptor indirectly
participated in the behavior of RPMI-8226 with bone cells using a novel triple-cell assay in vitro.
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Our results suggest that a functionally active P2X7 receptor is a target for intervention in the treatment
of myeloma-induced bone disease.
2. Materials and Methods
Six bona fide HMCL (RPMI-8226, U266, NCI-H929, OPM2, JJN3, and KMS12) were maintained as
per the description in the methods of the supplementary text. Cell culture reagent guidelines of ATCC
and/or DSMG were followed unless stated otherwise. Primary osteoblasts and osteoclasts [26,27] were
obtained from human volunteers after approvals from local ethics committees. Previously published
P2X7 receptor primers [28] and inventoried TaqMan assays were used for gene expression. Total protein
extracts (25 µg) were obtained from 3 subsequent passages and subjected to denaturing electrophoresis
on Mini-PROTEAN Tris-Glycine eXtended gels on 3 different occasions. PVDF membranes (0.2 µm)
were probed with P2X7R-ec (1.15 µg/mL) and P2X7R-Cter (0.6 µg/mL) and visualized by horseradish
peroxidase (HRP)-conjugated anti-mouse IgG and anti-rabbit IgG, respectively. All experiments were
performed when HMCL viability was determined as> 95% using trypan blue exclusion prior to seeding
and/or starting treatments. Pore formation and Ca2+ influx were measured on live HMCL by YO-PRO-1
and Fluo-4 AM, respectively. Cell viability was determined by cell proliferation reagent (WST-1) and
numbers by Quant-iT PicoGreen double stranded DNA. Apoptosis/necrosis (annexin V and propidium
iodide (PI)) and cell cycle progression (pulse with 10 µM BrdU for 2 h) were analyzed on FACSVerse.
A modified version of Boyden chamber with Corning HTS Transwell 96-well permeable supports
(1.0 µm) was used for co-cultures (Figure S1). Detailed protocols are provided as supplementary text.
3. Results
3.1. P2X7 Receptor Was Expressed and Induced Calcium Influx on HMCL
Pan-P2X7 receptor primers that recognize all variants resulted in a 400bp size amplicon confirming
a positive P2X7 receptor transcript (Figure 1A). Protein translation, using P2X7R-ec (recognizes epitopes
136–152 in the extracellular loop [29]) showed a ≈70kDa band in all HMCL (Figure 1B). An additional
band at ≈150 kDa may have been a dimeric P2X7 receptor protein due to an incomplete subunit
disassociation in our sample handling protocol. Next, P2X7 receptor pharmacology was determined
by (a) pore-formation assay (YO-PRO-1 fluorescence with 500 µM BzATP stimulus) and (b) Ca2+
influx (Fluo-4 fluorescence by rise in cytosolic [Ca2+] with 100 µM BzATP). For pore formation,
maximal YO-PRO-1 fluorescence (100%) was achieved by cell lysis at the end of each measurement.
All values obtained with agonist stimulus (500 µM BzATP) are expressed as percentage of maximal.
Pore dilation was significant in RPMI-8226 (64.9% versus 32% without agonist, p = 0.0067) and U266
(20.1% versus 14.2% without agonist, p = 0.0216) (Figure 1C). Pre-treatment with 10 µM AZ11645373,
a P2X7 receptor-specific antagonist, prevented the BzATP-induced pore formation in both HMCL
(25.9% in RPMI-8226, p = 0.0353 and 12.5% in U266, p = 0.0459). BzATP-induced pore-formation was
absent all other HMCL (Figure 1C, Table 1). Activation of P2X7 receptor ion channel and influx of
Ca2+ is expressed as peak fluorescence changed from baseline. Significant Ca2+ influx was seen in
all six HMCL (Figure 1D, Table 1). Influx was highest in OPM2 (2.50-fold, p = 0.0009) followed by
RPMI-8226 (2.46-fold, p = 0.0008), KMS12 (1.96-fold, p = 0.0002), U266 (1.77-fold, p = 0.0041), NCI-H929
(1.77-fold, p = 0.0001), and JJN3 (1.41-fold, p = 0.0413). Pharmacological blockade inhibited Ca2+ influx
in RPMI-8226 but not in other HMCL (Table 1). Collectively we showed expression in all six HMCL
but varying potency of agonist and a lacking inhibition with antagonists, reflecting differences in P2X7
receptor pharmacology between the HMCL.
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Figure 1. Expression and functionality of P2X7 receptor in RPMI-8226, U266, NCI-H929, OPM2, JJN3,
and KMS12 human multiple myeloma cell lines (HMCLs). (A) Semi quantitative RT-PCR shows the
P2X7 receptor mRNA expression in all HMCLs. Positive control was HEK293 cells stably transfected
with P2X7 receptor, negative control (–) was a no template PCR reaction, and GAPDH expression
corresponding to the same RT-PCR reaction was used as loading control. (B) Whole-cell lysates were
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immunoblotted with monoclonal antibody P2X7R-ec (raised against the extracellular domain of P2X7),
and GAPDH (bottom panel) was the loading control. (C) Pore formation shown as area under the curve
(AUC), with 500 µM 2′(3′)-O-(4-benzoylbenzoyl) adenosine 5′-triphosphate (BzATP) stimulus alone or
in the presence of 10 µM P2X7 receptor antagonists (KN62, A740003, or AZ11645373), as indicated.
Data are expressed as percentage of cell lysis (% maximum), achieved with injecting lysis reagent to
each well at the end of measurement, and shows mean ± SEM of 6–9 independent experiments (n)
with six replicate measurements per treatment (n = 2–4 with antagonists). * = p < 0.05, ** = p < 0.01,
Kruskal–Wallis comparison with multiple corrections of each treatment to 500 µM BzATP. (D) Influx of
Ca2+ evoked by 100 µM BzATP stimulus alone or in the presence of 1 µM P2X7 receptor antagonists
(KN62, A740003, or AZ11645373), as indicated. Data are expressed as cytosolic [Ca2+] measured by
peak fluorescence (Fmax) as a change from baseline (before stimulus, F0) and shows mean ± SEM of 5–7
independent experiments (n) with four replicate measurements per treatment (n = 2–5 with antagonists).
* = p < 0.05, Kruskal–Wallis comparison with multiple corrections of each treatment to 100 µM BzATP.
Table 1. Summary of P2X7 receptor pore formation and channel function induced by BzATP in
all HMCLs.
RPMI-8226 U226 NCI-H929 OPM2 JJN3 KMS12
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Bold represents significant p-Value
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3.2. P2X7 Receptor Expression, Function, and Signaling on RPMI-8226
Due to a variable pharmacology between the six HMCL, we utilized RPMI-8226 as a model
to understand the potential of P2X7 receptor signaling in myeloma biology. RPMI-8226 expresses
a pharmacologically sensitive P2X7 receptor and is also a common model of MM biology in vitro.
Structurally, the human P2X7 receptor gene (P2RX7) is alternatively spliced into 10 transcript variants
(www.ensembl.org). The full-length transcript designated as P2X7A has 13 exons and translates into
595 amino acid proteins. Nine variants are designated from P2X7B to P2X7J, but protein subunits
are reported from P2X7B (P2RX7-203) and P2X7J (P2RX7-211) [30–32]. Evidence that heteromeric
variant assembly alters the function usually associated with a homomeric P2X7A receptor [28],
and variable stoichiometry of P2X7A:B subunits alters ligand sensitivity compared to a homomeric
P2X7A receptor [30,33], provided a rationale to test these transcripts in RPMI-8226.
A 534bp amplicon (Figure 2A) and positive immuno-reactivity to P2X7R-ec and P2X7R-Cter
(C-terminal tail epitopes 576–595, APR-004) (Figure 2B) confirm the P2X7B variant. Quantitatively,
larger immuno-reactivity to P2X7R-ec indicate subunits with the extracellular loop in comparison to
the C-terminal tail (P2X7A). Flow cytometry after gating to exclude cell debris, doublets, and Hoechst
positivity showed the majority of RPMI-8226 with fluorescent P2X7R-ec (98%, solid line, Figure 2C).
Membrane permeabilization using 0.1% triton-X slightly reduced the positive population (94.8%,
dotted line, Figure 2C). Median fluorescence intensity (MFI), an index of receptor number per cell,
was reduced with permeabilization of RPMI-8226 (MFI = 561 versus 591 on intact cells), indicating
a decline in P2X7 receptor surface density. This was confirmed by microscopic visualization with
positive reactivity to P2X7R-ec on the majority of RPMI-8226 compared to a lower intensity, peri-nuclear
staining pattern with triton-X (Figure 2D).
To confirm our earlier observations of a functional P2X7 receptor on RPMI-8226, we performed a
detailed pharmacological analysis including a dose-dependent agonist response and antagonism with
P2X7 receptor antagonists. BzATP at doses ≥ 50 µM induced significant pore formation (p = 0.0072),
which was prevented by pretreatment with three different P2X7 receptor antagonists (Figure 2E).
IC50 values, calculated by non-linear curve with robust fit, were 0.05 µM, 0.85 µM, and 0.29 µM for
KN62, A740003, and AZ11645373, respectively (Figure 2E, inset). Similarly, BzATP-induced influx
of Ca2+ (p = 0.0040) was inhibited with KN62, A740003, and AZ11645373 pretreatment (Figure 2F).
IC50 values were 0.29 µM, 0.01 µM, and 0.03 µM for KN62, A740003, and AZ11645373, respectively
(Figure 2F, inset). Collectively, our results show the potency of BzATP and P2X7 receptor antagonists
in RPMI-8226.
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Figure 2. Characterization of P2X7 receptor in RPMI-8226. (A) Semi quantitative RT-PCR shows the
transcript for truncated variant of P2X7 receptor compared to HEK293 cells stably transfected with P2X7
receptor used a positive control. (B) Whole-cell lysates were immunoblotted with antibody P2X7R-Cter
(specific to the A isoform), showing a positive but lower intensity band compared to the P2X7R-ec
(common to both A and B isoforms); GAPDH (right panel) was the loading control. (C) Histograms
from flow cytometric analysis of intact (solid line) and permeabilized (dotted line) RPMI-8226 stained
with monoclonal antibody P2X7R-ec or negative control (no Ab) with only secondary antibody to
show percentage of positive cells (horizontal bar). (D) Microscopic images of RPMI-8226 stained
with monoclonal antibody P2X7R-ec when intact (top), permeabilized (middle), and with no primary
negative control (bottom). Hoescht was used to stain cell nuclei; scale bar 10 µm. (E) YO-PRO-1
uptake with increasing doses of BzATP shown as area under the curve (AUC) of maximum (cell lysis),
and (inset) with 500 µM BzATP against increasing doses of antagonists (KN62, A740003, or AZ11645373).
Injection trace of YO-PRO-1 uptake with BzATP (arrow marking the injection point) in the presence
or absence of 1 µM KN62, 1 µM A740003, or 1 µM AZ11645373. Data shows mean ± SEM of three
independent experiments (n) with six replicate wells per treatment (n = 2 with 6 replicate wells of each
antagonist concentration) and * = p < 0.05, Kruskal–Wallis comparison with multiple corrections of
each treatment to 0 µM BzATP. (F) Influx of Ca2+ evoked by increasing doses of BzATP, shown as peak
Cells 2020, 9, 2341 8 of 17
fluorescence (Fmax) as a change from baseline (before stimulus, F0), and (inset) by 100 µM BzATP
against increasing doses of antagonists (KN62, A740003, or AZ11645373). Injection trace of relative
fluorescence (arrow marking the injection point; ionophore was used for full response shown at dotted
arrow) in the presence or absence of 1 µM KN62, 1 µM A740003, or 1 µM AZ11645373. Data shows
mean ± SEM of four independent experiments (n) with three replicate wells per treatment (n = 2 with
duplicate wells of each antagonist concentration) and ** = p < 0.01, *** = p < 0.001, Kruskal–Wallis
comparison with multiple corrections of each treatment to 0 µM BzATP.
3.3. P2X7 Receptor Restricted Number of Viable RPMI-8226 by Cell Cycle Arrest and Not Apoptosis
Sustained P2X7 receptor activation induces RPMI- 8226 cell death [20]. Metabolic activity, as a
measure of viable RPMI-8226, was measured after chronic P2X7 receptor activation (300 µM BzATP
for 2 days). Viability was significantly reduced (28.2%, p = 0.0388) (Figure 3A) and comparable
to treatment with an extensively used anti-myeloma agent, Velcade (26.8% viability, p = 0.0135).
Curiously, 300 µM BzATP did not reduce dsDNA content, a measure of cell numbers (89.8% dsDNA
versus control) (Figure 3B), suggesting that the decline was independent of cell death. To determine
whether apoptosis is responsible for a lower percentage of viable cells, we assessed presentation
of plasma membrane protein annexin V (a marker of apoptosis), together with propidium iodide
(PI; permeant to dead cells). Flow cytometry showed no significant differences in the percentage
of viable (annexin V−PI−), apoptotic (annexin V+/PI−), and necrotic (annexin V+/PI+) RPMI-8226
after 2 days of BzATP treatment (Figure 3C). However, RPMI-8226 demonstrated high variability
between the four experimental replicates and even treatment with Velcade, a known mechanism via
cell apoptosis, failed to induce apoptosis in our study. Therefore, we immunoblotted for caspase-3,
a P2X7 receptor-dependent caspase, for apoptotic activity and cell death. BzATP reduced caspase-3
cleavage (17 kDa) (0.42-fold, Figure 3D), reflecting a reduction in apoptosis of RPMI-8226.
Myeloma cells have several mechanisms that allow them to evade apoptosis and contribute to
their survival. One such phenomenon is an evolved cell-cycle behavior, and while disruptors of
cell cycle progression are not fully understood, patient relapses are attributed to the cycle re-entry
and subsequent expansion of the malignant clone. Therefore, we assessed the cell-cycle behavior
of RPMI-8226 using BrdU, an analog of thymidine readily incorporated into DNA during DNA
synthesis. Alive cells were gated and grouped into G0/G1 (quiescent cells or cells preparing for growth),
S (cells with active DNA synthesis), and G2/M (cell growth immediately followed by formation of
daughter cells) phases together with total DNA content from Hoechst stain (Figure 3E). Treatment
with 300 µM BzATP resulted in a significant accumulation of RPMI-8226 in S phase (61.5%, p = 0.0014)
(Figure 3F). Compared to respective untreated controls, a concomitant reduction was seen in G0/G1
(5.2%, p = 0.0086) and G2/M (23.5%, p = 0.0015) phases (Figure 3F). Decline in proportion of RPMI-8226
in S phase was detected when performing BrdU labelling after a further 24 h (54.2%) (Figure 3F).
–








Figure 3. P2X7 receptor induced cell cycle arrest but not apoptosis in RPMI-8226. (A) Viability as a
measure of metabolically active and (B) DNA content (pg/well) of RPMI-8226 cells after 48 h with BzATP
is plotted as a percentage of control (0 µM BzATP, dotted line). Velcade (100 nM), an anti-myeloma
agent, was used as a positive control. Data shows mean ± SEM of three independent experiments;
Kruskal–Wallis comparison to show * = p < 0.05 multiple corrections of each treatment to 0 µM BzATP
(# = p < 0.05, ### = p < 0.001 Mann–Whitney test for 0 µM BzATP vs. Velcade). (C) Flow cytometry
to assess the percentage of alive (annexin V-/PI-), apoptotic (annexin V+/PI-), and necrotic (annexin
V+/PI+) cells after 48 h with 300 µM BzATP. Data shows mean ± SEM of four independent experiments.
(D) Western blot analysis to quantify caspase-3-cleaved protein (17 kDa) as a ratio of total protein
(35 kDa) after 48 h with 300 µM BzATP; GAPDH was probed as a loading control (n = 3). (E) Scatter
diagrams representing the populations in G0/G1, S, and G2/M phases of the cell cycle as determined by
flow cytometry and (F) analysis following a 2-h BrdU pulse showing the percentage of cells in each
cell cycle phase after 48 and 72 h treatment with 300 µM BzATP. Data shows mean ± SEM of three
independent experiments, where * = p < 0.05 by Mann–Whitney test compared to 0 µM BzATP in the
corresponding cell cycle phase.
3.4. P2X7 Receptor Activation Deregulated Phosphorylation of NF-κB in RPMI-8226
Ultimately, myeloma cell biology is altered by key transcription regulators such as extracellular
signal-regulated kinases (ERK1/2), signal transducer and activator of transcription 3 (STAT3),
and nuclear factor-κappa B (NF-κB). Treatment with 300 µM BzATP caused a rapid phosphorylation of
ERK1/2 (pERK1/2) but phosphorylation of STAT3 (pSTAT3) was reduced in two out of three biological
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replicates (data not shown). We speculate the inconsistency was due to failing to separate the nuclear
and cytosolic components for analysis. It is known that transcriptional regulation, although activated
within the nucleus, is often already initiated with the transcription factor bound to cytoplasmic DNA
causing a nuclear localization signal prior to targeting the nucleus. Moreover, transcriptional activators
associate with other transcriptional co-activator and repressor complexes to ensure long term changes
in gene transcription. One such transcriptional activator is p65 subunit of the NF-κB transcription
factor complex [34]. We saw a significant reduction in the phosphorylation of p65 after 90 min of
300 µM BzATP in RPMI-8226 (0.49-fold, p = 0.0286) (Figure 4A).
κB in RPMI
κappa B κB). Treatment with 300
κB
– –
κappa B (NF κB κB κB;
Figure 4. P2X7 receptor activation of transcription regulators and subsequent alterations in
RPMI-8226–osteoblast and RPMI-8226–osteoclast interaction. (A) Western blot to show the nuclear
factor-κappa B (NF-κB) phosphorylation using phosphorylation of NF-κB (p-NF-κB; p65) antibody and
quantification of phosphorylated protein normalized to the total protein t-NF-kB (p65) after 90 min
treatment with 300 µM BzATP. GAPDH was probed as a protein loading control. (B) TaqMan qPCR
analysis showing the expression of gp80 and gp130 after 90 min treatment with BzATP (300 µM) alone,
or after a 30-min pre-treatment with the antagonist (AZ11645373+ 300 µM), as indicated. Data shows
change in mean ± SEM of four independent experiments (n) as a fold change of untreated control
(0 µM); beta-actin and GAPDH were used as housekeeping genes. (C) Effects of RPMI-8266 treatment
with 300 µM BzATP for 90 min before culturing with bone cells for 48 h in an in vitro co-culture assay.
The effect on viability of RPMI-8266 (HMCL) in the presence of osteoblasts (HMCL+ OB), osteoclasts
(HMCL+ OC), or both osteoblasts and osteoclasts (HMCL+ OB + OC) (D), and on mineralization and
resorption (E). Data shows mean ± SEM of independent experiments and * = p < 0.05 by Mann–Whitney
test comparing the effect of BzATP treatment or by Kruskal–Wallis comparison to compare the effect of
bone cells, or # = p < 0.05 by Mann–Whitney comparison to baseline bone cell function (dotted line) as
indicated (n = 3, RPMI-8266 viability; n = 4, mineralization; and n = 2, resorption). Representative
images to show (F) Alizarin Red-stained mineralized nodules (white arrows heads) as a measure of
osteoblast function (scale bar: 500 µm) and (G) resorption (white stars) on dentine discs as a measure
of osteoclast function (scale bar: 100 µm; in vitro).
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Phosphorylation of p65 subunit has received the most attention in studies of NF-κB
phosphorylation thus far. p65 heightens inflammatory cytokine production in myeloma bone disease,
such as the release of interleukin-6 (IL-6) by associating with members of the IL-6 signaling complex [35].
IL-6 signal transduction relies on co-expression of two transmembrane molecules (gp80 and gp130) to
constitute a functional IL-6 receptor (IL-6R). The smaller subunit (gp80) must associate with a larger
structure of gp130 for high affinity binding and IL-6 signaling. On the contrary, gp130 alone acts
as a signal transducer that is responsible for a variety of biological activities [36]. gp130 signaling
is an important driver of MM pathogenesis [37,38]. RPMI-8226 express both gp80 and gp130 while
IL-6 is absent [39,40]. We tested if the components of IL-6 signal transduction are regulated by the
P2X7 receptor. RPMI-8226 were treated with 300 µM BzATP and the supernatant was collected at
time intervals. IL-6 secretion was undetected by ELISA even at 48 h, which corresponded to lower
mRNA copy numbers of IL-6 transcript in RPMI-8226 cells (> 35 Ct values, data not shown). Both gp80
(IL-6R) and gp130 transcripts were regulated after P2X7 receptor activation. Downregulation of
gp80 (0.95-fold and 0.86-fold normalized to housekeeping gene beta-actin and GAPDH, respectively)
and upregulation of gp130 (1.28-fold and 1.19-fold normalized to housekeeping gene beta-actin and
GAPDH, respectively) after P2X7 receptor activation RPMI-8226 was observed (Figure 4B).
3.5. P2X7 Receptor Restricted RPMI-8226 Growth even in the Presence of the Bone Cells and Altered
RPMI-8226–Osteoblast and RPMI-8226–Osteoclast Interactions
Targeting the bone–myeloma interdependence has been explored with interest as a therapy
for MM patients. We explored whether P2X7 receptor has consequences for the myeloma–bone
interaction using a co-culture assay to assess four conditions: RPMI-8226 (1) treated with 300 µM
BzATP for 90 min, with or without a 30 min antagonist pretreatment (HMCL), (2) treated and then
co-cultured with mature primary osteoblasts (HMCL+OB), (3) treated and then co-cultured with
resorbing osteoclasts (HMCL+OC), and (4) treated and then co-cultured with both bone cells (HMCL +
OB + OC). All analyses were performed after 2 days.
First, a regulation of RPMI-8226 viability by bone cells was seen in our 3D co-culture model.
Osteoblasts restricted RPMI-8226 proliferation (31.93% HMCL + OB versus HMCL, white) (Figure 4C)
while osteoclasts favored it (237% HMCL + OC versus HMCL, white). Osteoblasts and osteoclasts
(HMCL + OB + OC) reduced RPMI-8226 viability to 24.95% compared to the RPMI-8226 monoculture
(Table 2). We next determined whether direct effects of P2X7 receptor activation observed previously
(Figure 3A) were maintained. Significant reduction in RPMI-8226 viability with 300 µM BzATP (13.78%,
p = 0.0070, green) and partial reversal with antagonist pretreatment (48.47%, blue) confirmed the P2X7
receptor-mediated effect on RPMI-8226 (Figure 4C, Table 2). Most interestingly, primary bone cells
altered the behavior of activated RPMI-8226 when compared to the non-activated controls. Osteoblasts
(HMCL + OB) synergized the effect of P2X7 receptor as viability of RPMI-8226 was further inhibited
(8.81% with 300 µM BzATP, p = 0.0526 versus 31.93% with 0 µM BzATP). However, this inhibition
was presumably due to a dominant osteoblastic effect and was not mediated by P2X7 receptor, as any
reversal with antagonist pretreatment of RPMI-8226 was lacking (11.71% with 1 µM AZ11645373).
On the other hand, osteoclasts no longer maintained a pro-myeloma effect on activated RPMI-8226
(16.59% with 300 µM BzATP, p = 0.0073 versus 237% with 0 µM BzATP) but could be prevented with
P2X7 receptor antagonist (135.8% with 1 µM AZ11645373) (Figure 4C). Presence of both osteoblasts
and osteoclasts (HMCL + OB + OC) reduced RPMI-8226 viability (13.33% with 300 µM BzATP versus
25% with 0 µM BzATP) and was prevented by P2X7 receptor antagonist (25% with 1 µM AZ11645373),
but these findings did not reach statistical significance (Table 2). Together, these data show that
osteoblasts exerted a dominant effect on RPMI-8226 inhibition, which, in spite of an osteoclastic growth
promotion of myeloma cells, was synergistic to the P2X7 receptor-induced growth arrest.
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Table 2. Effect of P2X7 receptor activation of RPMI-8266 interaction with osteoblasts and osteoclasts in 3-cell culture set up in vitro.
HMCL HMCL + OB p-Value HMCL + OC p-Value HMCL + OB + OC p-Value
Viability, % mean ± SEM (n = 3)
0 µM 100 ± 0.01 31.93 ± 10.08 0.1403 237.0 ± 12.75 0.3073 24.95 ± 5.31 0.1123
300 µM 13.78 ± 0.79 8.81 ± 2.12 16.59 ± 0.74 13.33 ± 3.63
p-value 0.0070 0.0526 0.0073 0.1797
10 µM AZ11645373
+ 300 µM BzATP
48.47 ± 2.30 11.71 ± 4.83 135.8 ± 10.46 25.20 ± 11.54
p-value 0.1779 0.4561 0.1797 0.3711
Mineralization, % of OB mean ± SEM (n = 4)
0 µM
-
10.65 ± 3.54 0.0579
-
4.44 ± 2.54 0.0038
300 µM 24.57 ± 4.91 53.94 ± 9.84
p-value 0.1143 0.0286
Resorption, % of OC mean ± SEM (n = 2)
0 µM
- -
177.9 ± 1.36 0.2781 31.09 ± 27.21 0.2781
300 µM 174.3 ± 78.82 100.8 ± 8.72
p-value >0.999 0.333
Bold represents significant p-Value
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Next, we examined if P2X7 receptor alters the interaction of RPMI-8226 with bone cells as
interrupting the myeloma-bone interdependence is imperative to disrupt metabolic bone disease.
The extent of mineral deposition provides valuable insight about the process of bone formation and acts
as a measure of osteoblast function in vitro. Osteoblastic mineralization was reduced in the presence
of RPMI-8226 (10.7% of baseline, dotted line, p = 0.0579), which remained suppressed with their P2X7
receptor activation (24.57%, green bar HMCL +OB) (Figure 4D). Triple culture with osteoclasts (HMCL
+ OB + OC) did not affect the RPMI-8226-mediated inhibition of osteoblastic mineralization (4.44% of
baseline, dotted line, p = 0.0038). However, osteoblast function was uplifted with P2X7 receptor
activation of RPMI-8226 (53.94% versus 0 µM BzATP, p = 0.0286) (Figure 4D). These results show that
P2X7 receptor induces a growth arrest in RPMI-8226 and the presence of osteoclasts is effective in
restoring the myeloma-induced inhibition of osteoblastic function.
To assess osteoclast function, we evaluation percentage of resorption of a bone substrate. Increased
osteoclastic resorption in the presence of RPMI-8226 (177.9% of baseline, dotted line) remained
unchanged with their P2X7 receptor activation (174.3%, green bar Figure 4D) (HMCL + OC). Presence
of osteoblasts (HMCL + OB + OC) diminished the RPMI-8226-mediated pro-osteoclastic effect
(31.09% resorption of baseline, dotted line). However, osteoclast function was restored in the presence
of RPMI-8226 previously treated with 300 µM BzATP (100.8% versus 0 µM, Figure 4E). In all, while
osteoclast function was heightened by RPMI-8226, the excessive resorption was prevented by their
P2X7 receptor when osteoblasts were also present.
4. Discussion
P2X7 receptor has an ambiguous role in cancer progression with both pro- and anti-cancerous
effects, depending on the cancer or tumor cell type. Its role in myeloma biology and relevance in
the consequent bone disease is not defined. We used RPMI-8226 to show that human P2X7 receptor
induces S phase cell cycle arrest and alters transcriptional regulation to reduce the myeloma growth.
Further, our co-culture model demonstrated in vitro that P2X7 receptor regulates the crosstalk of
RPMI-8226 with osteoblast and that a synergistic bone anabolic therapy can be explored. We also
speculate that the reversal of hyperactive osteoclast function in vitro represents a normalized bone
turnover, mitigating the pathology of the bone disease.
Our exploratory findings provide a rationale for advancing the research in P2X7 receptor-mediated
MM progression. A functional P2X7 receptor is seen by conventional methods such as (a) membrane
permeability and (b) Ca2+ influx following agonist stimulus on HMCLs. These HMCLs represent
diversity of tissue origin and patient disease stage, which may explain the differences in agonist
potency. These differences in pharmacology are highly relevant for translation into the clinic as the
diversity of clones in metastatic diseases is known to affect responses to therapies. Pre-clinical models
reflecting patient-to-patient variability are highly warranted to address the superiority of P2X7 receptor
as an independent drug target, or in synergy with drug combinations, in MM patients. Additional
complexity to the regulatory functions of P2X7 receptor is provided by the highly polymorphic
human P2X7 receptor gene (P2RX7). Several single nucleotide polymorphisms (SNPs) increase or
decrease association to disease susceptibility [41]. An association to the risk of myeloma is described
with contrasting results [42,43]. Furthermore, the two isoforms P2X7A and P2X7B impart different
functional properties [28], and co-expression of both is required for the P2X7 receptor membranal
pores. It is speculated that a homo/heteromeric P2X7A/B receptor may be advantageous to cancer cells
during increased eATP [44] and a ligand-induced acquisition of varying stoichiometry of subunits
may determine cell survival/death [30]. Moreover, RPMI-8226 are capable of active P2X7 receptor
modulation, as expression increases to several-fold when exposed to high eATP [45]. We saw a strong
immunoreactivity to both P2X7 receptor antibodies, implying a functional protein composed of both
P2X7A and B subunits (Figure 2A). Thus, depending on the stimulus, a ligand-induced P2X7 receptor
modulation may support their growth or trigger death. We observed a RPMI-8226 cycle arrest as
one of the events (Figure 3F). Thus far, P2X7 receptor-mediated shedding of cell surface molecules
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CD23 and CXCL16 with cytokine-like activities, as well as a loss of plasma membrane integrity,
are indicated in RPMI-8226 [20,21]. While an increase in circulating levels of CD23 and CXCL16 (both
being cell membrane bound signaling proteins) may have consequences in the pathology of MM
disease, induction of cell death/necrosis seems counter-intuitive for progression. RPMI-8226 show
significant decline in cell viability without a reduction in cell numbers (Figure 3A,B). A consistent
induction of apoptosis and necrosis was not achieved in our study, and even caspase-3 cleavage was
reduced. P2X7 receptor activation could have triggered a “danger signal” where cell cycle arrest is
used as a protective mechanism. Downregulation of p65 NF-κB signaling also indicated a protective
mechanism by suppressing proliferation (Figure 4C). We acknowledge that these effects are transient,
as activation of NF-κB, ERK1/2, and STAT3 signaling are critical growth and survival pathways during
drug-induced apoptosis. Aligning with this, S phase arrest was already lifted at the 72 h timepoint
(Figure 3F). Nevertheless, P2X7 receptor activation may induce P2X7 subunit modulation and thus an
expansion of RPMI-8226 clones with a new phenotype. These resultant clones may be resistant and
desensitized to a similar signal, thus acquiring a survival benefit. One of the mechanisms by which
myeloma cells develop multi-drug resistance is associated with poor prognosis in patients.
Homeostatic bone turnover requires a precise activity between the bone cells and MM patients
present with a severe bone destruction. Myeloma-derived factors cause hyperactivation of osteoclasts
and suppression of osteoblast differentiation orchestrated by paracrine and endocrine factors such
as cytokines and various signaling molecules [46,47]. Our co-culture model helps understand the
direct interaction between these three cells, shielded from any external regulation. We not only found
an osteoblastic suppression and osteoclastic hyperactivation of RPMI-8226 (Figure 4C), but also a
dominant osteoblastic suppression, regardless of a pro-myeloma osteoclastic effect. The former was
exacerbated via P2X7 receptor. We speculate that a temporary arrest of RPMI-8226 growth assists
the osteoblast inhibition, but more studies are needed to confirm a long-term effect. Moreover, P2X7
receptor regulates the lifespan and activity of osteoclasts and inhibits osteoblast function [48,49].
This potential for P2X7 receptor may support the case for an anabolic/dual bone therapy in MM patients
and will influence overall bone turnover in patients with an active bone disease.
In conclusion, we show the variations in P2X7 receptor structure in myeloma cells as well
as striking pharmacological differences, particularly in terms of the agonist profile. Although the
signaling and growth factors require further investigation, we surmise that P2X7 receptor directly
influences the myeloma–osteoblast and myeloma–osteoclast cross talk and therefore acknowledge
the potential of P2X7 receptor as a target in MBD. Our study lacks an in vivo model supporting this
potential, and pre-clinical investigations are needed to have a relevant transitional effect on patients.
A heterogeneity in P2X7 receptor expression, potential of subunit co-assembly, and eATP-driven
modulation of P2X7 receptor isoforms may all be important determinants in clonal progression.
To have a therapeutic effect, an ideal modulator would be selective between the P2X7 receptor variants
such as the blocking antibody targeted against a non-functional P2X7 receptor epitope currently being
explored in clinical trials [50]. The time for intervention will also be key in the feasibility of the P2X7
receptor as a therapy for MM patients. Equally imperative will be to understand the effect on healthy
cell subsets, but ATP administration appears to be a promising strategy in leukemia treatment [51].
Lastly, as alleles imparting a loss of function to the gene for human P2X7 receptor are associated
with an increased risk of MM, our findings support that a complete activation of P2X7 receptor is
more relevant in the pathology of MM and the eventual treatment of myeloma-induced bone disease.
Therefore, a potential therapy will involve a personalized, timely, and limited intervention with a P2X7
receptor modulator, potentially in combination with an existing treatment.
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